SCHEMBL22290264

SCHEMBL22290264

O=C1c2ccccc2C(=O)N1Cc1ncncc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.48
CYP1A2 P05177 7/20 0.44
CYP2C19 P33261 4/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
RPS6KA2 Q15349 1/20 0.43
ALDH1A1 P00352 4/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP3A4 P08684 6/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PKM P14618 1/20 0.41
CYP1B1 Q16678 2/20 0.40
POLB P06746 1/20 0.40
USP2 O75604 4/20 0.39
MAPK1 P28482 3/20 0.39
CYP2C9 P11712 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22290229 0.86 MEN1 (0.47) CASP3CYP1A2CYP2C19ALDH1A1HPGD
SCHEMBL2894639 0.76 CYP1B1 (0.48) CASP3RAB9AALDH1A1MEN1KMT2A
SCHEMBL2888208 0.76 MEN1 (0.46) CASP3CYP1A2CYP2C19NPC1RAB9A
SCHEMBL22290248 0.76 CYP1A2 (0.56) CASP3CYP1A2CYP2C19NPC1RAB9A
SCHEMBL22309089 0.75 CASP3 (0.49) CASP3CYP1A2CYP2C19NPC1RAB9A
SCHEMBL22290226 0.72 CYP1A2 (0.43) CYP1A2CYP2C19ALDH1A1LMNAHPGD
SCHEMBL22290219 0.72 CYP1A2 (0.43) CYP1A2CYP2C19ALDH1A1HPGDCYP3A4
SCHEMBL4424799 0.72 CASP3 (0.79) CASP3CYP1A2CYP2C19RPS6KA2ALDH1A1
SCHEMBL4417314 0.72 CASP3 (0.59) CASP3CYP1A2CYP2C19NPC1RAB9A
SCHEMBL19835809 0.72 CASP3 (0.56) CASP3CYP1A2CYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387968-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2021-12-16 US disclosed
EP-3917919-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2021-12-08 EP disclosed
WO-2020160213-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed
WO-2020160213-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387968-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLH, POLB CASP3 3863/4885CYP1A2 931/4885CYP2C19 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.